CAMBRIDGE, Mass. and EXTON, Pa., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a
clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare
diseases, today announced that the company will present at the 35th Annual J.P. Morgan Healthcare Conference on
Wednesday, January 11, 2017 at 11:00 a.m. Pacific Time (2:00 p.m. Eastern Time) at the Westin St. Francis in San Francisco. Idera’s
Chief Executive Officer, Vincent Milano, will present a corporate overview and provide an update on the company’s plans and
expectations for 2017.
Live audio webcasts of Idera’s presentation and following Q&A session will be accessible in the Investors and Media section
of Idera’s website at http://www.iderapharma.com. An archived version will also be available on the Company’s
website after the event for 90 days. As a convenience to investors, a copy of the company’s presentation will be posted on
the Idera corporate website at 8:00 a.m. Eastern Time on Monday, January 09, 2017.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment
of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic
oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera
has created a third generation antisense technology platform using its proprietary technology to inhibit the production of
disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile) rdoody@iderapharma.com
